HomeInvestingEli Lilly 2022 gains grow to 20% as it lays out plan...

Eli Lilly 2022 gains grow to 20% as it lays out plan for obesity drug, tirzepatide

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

New Updates